Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Cancer Cell|June 10, 2015
Excluding T Cells: Is β-Catenin the Full Story?Siwen Hu-Lieskovan, Blanca Homet Moreno, Antoni Ribas
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 10, 2010
Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomasBlanca Homet Moreno, Elena Garralda Cabanas, Ricardo Hitt
Seminars in Oncology|May 13, 2015
Anti-PD-1 therapy in melanomaBlanca Homet Moreno, Giulia Parisi, Lidia Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2014
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challengesSiwen Hu-Lieskovan, Lidia Robert, Blanca Homet Moreno, et al.
Oncoimmunology|September 14, 2016
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanomaBlanca Homet Moreno, Stephen Mok, Begonya Comin-Anduix, et al.
Clinical Genitourinary Cancer|August 23, 2020
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United StatesOliver Hale, Karl Patterson, Yizhen Lai, et al.
Frontiers in Oncology|October 18, 2023
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinomaGurjyot K Doshi, Haojie Li, Mehmet Burcu, et al.
Journal of Medical Economics|May 16, 2020
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United StatesRachael Louise Slater, Yizhen Lai, Yichen Zhong, et al.
Science Translational Medicine|March 20, 2015
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanomaSiwen Hu-Lieskovan, Stephen Mok, Blanca Homet Moreno, et al.
Oncotarget|February 2, 2017
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factorSean Caenepeel, Keegan Cooke, Sarah Wadsworth, et al.
Pageof 5